RANITIDINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ajanta Pharma Ltd	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	CAPSULE;ORAL	209859	ANDA	Ajanta Pharma USA Inc.	27241-109-06	60 CAPSULE in 1 BOTTLE (27241-109-06)	2018-09-27
Ajanta Pharma Ltd	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	CAPSULE;ORAL	209859	ANDA	Ajanta Pharma USA Inc.	27241-109-50	500 CAPSULE in 1 BOTTLE (27241-109-50)	2018-09-27
Ajanta Pharma Ltd	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	CAPSULE;ORAL	209859	ANDA	Ajanta Pharma USA Inc.	27241-110-03	30 CAPSULE in 1 BOTTLE (27241-110-03)	2018-09-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the global supply landscape for Ranitidine Hydrochloride Active Pharmaceutical Ingredient (API), identifying key manufacturers, their production capacities, and significant market trends. The analysis focuses on identifying reliable suppliers for pharmaceutical companies requiring consistent and high-quality API for finished dosage forms.

Who are the primary manufacturers of Ranitidine Hydrochloride API?

The production of Ranitidine Hydrochloride API is concentrated among a select group of global manufacturers, with a significant presence in India and China. These entities supply the API to generic drug manufacturers worldwide. Key players identified include:

Aurobindo Pharma Ltd.: An Indian multinational pharmaceutical company with a broad portfolio of generic drugs. Aurobindo has established manufacturing facilities for various APIs, including Ranitidine Hydrochloride.
Dr. Reddy's Laboratories Ltd.: Another prominent Indian pharmaceutical company. Dr. Reddy's is known for its integrated operations, from API manufacturing to finished formulations, and produces Ranitidine Hydrochloride.
Laurus Labs Ltd.: An Indian biopharmaceutical company primarily focused on API manufacturing. Laurus Labs is a significant supplier of APIs across multiple therapeutic areas, including gastrointestinal medications.
Divi's Laboratories Ltd.: A leading Indian manufacturer of APIs and custom synthesis solutions. Divi's operates large-scale facilities and is a known producer of Ranitidine Hydrochloride.
Zydus Lifesciences Ltd. (formerly Cadila Healthcare Ltd.): A global life sciences company headquartered in India. Zydus manufactures a wide range of pharmaceutical products, including APIs like Ranitidine Hydrochloride.
Ansuar Pharmaceutical Co., Ltd.: A Chinese pharmaceutical company involved in the production of APIs and intermediates.
Zhejiang Huahai Pharmaceutical Co., Ltd.: A major Chinese pharmaceutical manufacturer with substantial API production capabilities, including for Ranitidine Hydrochloride.

These companies operate under stringent regulatory oversight, adhering to Good Manufacturing Practices (GMP) standards required by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What is the current market status for Ranitidine Hydrochloride API?

The market for Ranitidine Hydrochloride API has experienced significant shifts in recent years, primarily due to regulatory actions concerning potential N-nitrosodimethylamine (NDMA) contamination.

In September 2019, the U.S. Food and Drug Administration (FDA) announced that it had detected NDMA, a probable human carcinogen, in ranitidine products. This led to widespread recalls and subsequent market withdrawals. Similar actions were taken by regulatory authorities in other major markets, including the European Union and Canada.

Consequently, the demand for Ranitidine Hydrochloride API from finished dosage manufacturers in these regions has drastically declined. Manufacturers who previously produced Ranitidine Hydrochloride have either ceased production, redirected capacity to other APIs, or significantly scaled back operations for this specific product.

While global demand has reduced, some markets with less stringent regulatory oversight or those that have not implemented similar withdrawal mandates may still exhibit demand. However, the overall global volume of Ranitidine Hydrochloride API produced and traded has contracted significantly.

The absence of ranitidine from major markets has led to increased reliance on alternative medications for acid reflux and ulcer treatment, such as proton pump inhibitors (PPIs) and H2 blockers like Famotidine. This shift has impacted the API supply chain, with manufacturers of alternative APIs experiencing increased demand.

What are the key manufacturing regions and their production capabilities?

The primary manufacturing hubs for Ranitidine Hydrochloride API have historically been India and China. These regions possess established chemical synthesis infrastructure and a large workforce experienced in API production.

India: Indian pharmaceutical companies have been major global suppliers of APIs, including Ranitidine Hydrochloride, due to competitive manufacturing costs and strong regulatory compliance capabilities for export markets. Companies like Aurobindo Pharma, Dr. Reddy's Laboratories, Laurus Labs, Divi's Laboratories, and Zydus Lifesciences have had substantial API production capacity. Following the regulatory actions, the utilization of their Ranitidine Hydrochloride production lines has been significantly curtailed.

China: Chinese manufacturers, including Zhejiang Huahai Pharmaceutical and Ansuar Pharmaceutical, have also been significant contributors to the global Ranitidine Hydrochloride API supply. China's large-scale chemical industry and API production infrastructure have made it a cost-effective source for many pharmaceutical ingredients. Similar to India, Chinese API producers have also seen a reduction in demand for Ranitidine Hydrochloride for export to regulated markets.

The production capabilities of these manufacturers are typically measured in metric tons per annum. Before the widespread market withdrawals, capacities for Ranitidine Hydrochloride among leading players could range from several hundred to over a thousand metric tons annually, depending on the company's scale and market focus. However, current operational capacities are likely significantly lower and may be on a toll manufacturing or on-demand basis rather than continuous large-scale production for inventory.

What are the regulatory considerations for Ranitidine Hydrochloride API suppliers?

Suppliers of Ranitidine Hydrochloride API are subject to rigorous regulatory scrutiny, particularly for markets like the United States, Europe, and Japan. Key considerations include:

Good Manufacturing Practices (GMP): Adherence to GMP standards is mandatory. This includes detailed documentation, quality control, facility maintenance, and process validation to ensure product quality, safety, and consistency. Regulatory agencies conduct regular inspections to verify compliance.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. A DMF contains confidential, detailed information about the facilities, processes, and materials used in the manufacturing of an API. This allows drug product manufacturers to reference the DMF in their own regulatory submissions (e.g., Abbreviated New Drug Applications - ANDAs) without disclosing proprietary information.
Impurity Profiling and Control: The detection of NDMA in ranitidine products has placed an unprecedented emphasis on impurity control. API suppliers must demonstrate robust analytical methods for detecting and quantifying impurities, including nitrosamines, at very low levels. Process chemistry must be optimized to minimize the formation of such impurities during synthesis.
Stability Studies: Comprehensive stability studies are required to establish the shelf-life of the API under various storage conditions. This data is crucial for ensuring the API maintains its quality and potency over time.
Recalls and Market Withdrawals: The regulatory landscape for Ranitidine Hydrochloride is dominated by the history of recalls. Suppliers must have robust recall procedures in place and be prepared to respond to regulatory requests for product information and market withdrawal actions.
Geographical Restrictions: Due to the regulatory actions, Ranitidine Hydrochloride API is effectively unavailable or not permitted for use in finished dosage forms in major regulated markets. Suppliers catering to these markets must acknowledge this. Export to regions with different regulatory frameworks or those that have not implemented similar bans would require compliance with the specific import regulations of those countries.

The current regulatory environment effectively restricts the market for Ranitidine Hydrochloride API, forcing suppliers to focus on remaining niche markets or pivot to alternative product lines.

What are the alternatives to Ranitidine Hydrochloride for drug manufacturers?

With Ranitidine Hydrochloride largely withdrawn from major pharmaceutical markets, drug manufacturers have shifted their focus to alternative therapeutic agents. The primary alternatives fall into two main classes:

Proton Pump Inhibitors (PPIs): This class of drugs is generally considered more potent than H2 blockers in reducing stomach acid production. Common PPIs include:
- Omeprazole (e.g., Prilosec)
- Esomeprazole (e.g., Nexium)
- Lansoprazole (e.g., Prevacid)
- Pantoprazole (e.g., Protonix)
- Rabeprazole (e.g., AcipHex) The APIs for these drugs are manufactured by numerous global suppliers, and their markets have seen increased demand.
H2 Receptor Antagonists (H2 Blockers): Besides ranitidine, other H2 blockers remain available and are used for conditions like heartburn, acid indigestion, and ulcers. The most prominent alternative in this class is:
- Famotidine (e.g., Pepcid) Famotidine has largely replaced ranitidine in many formulations and over-the-counter products. Its API is widely manufactured and available.
- Cimetidine (e.g., Tagamet) is another H2 blocker, but its use has declined due to drug interaction profiles and the availability of more effective alternatives.

For drug manufacturers, the transition involves sourcing APIs for these alternative medications. This requires establishing new supplier relationships, ensuring the quality and regulatory compliance of the new APIs, and potentially reformulating their finished dosage products. The API suppliers who previously produced Ranitidine Hydrochloride may have the capacity and expertise to pivot to manufacturing APIs for these alternative drug classes, provided they have the necessary regulatory approvals and market interest.

Key Takeaways

Global supply of Ranitidine Hydrochloride API has significantly diminished due to regulatory withdrawals in key markets, primarily related to NDMA contamination concerns.
Major API manufacturers in India (Aurobindo Pharma, Dr. Reddy's Laboratories, Laurus Labs, Divi's Laboratories, Zydus Lifesciences) and China (Ansuar Pharmaceutical, Zhejiang Huahai Pharmaceutical) were the primary suppliers.
Current demand for Ranitidine Hydrochloride API is largely confined to niche markets or regions not enforcing similar withdrawal mandates.
The market has shifted towards alternative medications, notably Proton Pump Inhibitors (PPIs) and other H2 blockers like Famotidine.
API suppliers must navigate stringent regulatory requirements, including GMP, DMF filings, and robust impurity control, especially concerning nitrosamines.

Frequently Asked Questions

What is the primary reason for the decline in Ranitidine Hydrochloride API supply?

The primary reason is the detection of N-nitrosodimethylamine (NDMA), a probable carcinogen, in ranitidine products, leading to recalls and market withdrawals by regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA).

Which countries were most affected by the Ranitidine Hydrochloride market withdrawal?

The United States, European Union member states, and Canada were among the most significantly affected markets where ranitidine products were withdrawn.

Have all manufacturers stopped producing Ranitidine Hydrochloride API?

While production has drastically reduced for major markets, some manufacturers may continue to produce limited quantities for specific regions with different regulatory stances or for research purposes, though this is not widespread.

What are the main regulatory bodies that impacted Ranitidine Hydrochloride supply?

The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and other national regulatory authorities have issued warnings, requested recalls, or mandated market withdrawals, directly impacting API supply.

How can a pharmaceutical company secure an alternative API if their Ranitidine Hydrochloride supply is disrupted?

Companies should identify alternative therapeutic classes (e.g., PPIs, Famotidine), research API manufacturers for these alternatives, review their regulatory compliance (e.g., GMP, DMFs), and initiate new supplier qualification processes.

What are the key quality control challenges for API suppliers in the current environment?

The main challenge is demonstrating the absence or control of nitrosamine impurities at extremely low levels, requiring advanced analytical methods and optimized manufacturing processes.

Cited Sources

[1] U.S. Food and Drug Administration. (2019, September 24). FDA takes additional action to protect patients from potentially harmful nitrosamine impurity in ranitidine. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-takes-additional-action-protect-patients-potentially-harmful-nitrosamine-impurity-ranitidine [2] European Medicines Agency. (2020). EMA recommends restrictions on ranitidine-containing medicines. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/news/ema-recommends-restrictions-ranitidine-containing-medicines [3] Health Canada. (2019, October 18). Health Canada takes action on ranitidine products. Health Canada. Retrieved from https://www.canada.ca/en/health-canada/news/2019/10/health-canada-takes-action-on-ranitidine-products.html [4] Company websites and publicly available annual reports for Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Laurus Labs Ltd., Divi's Laboratories Ltd., Zydus Lifesciences Ltd., Ansuar Pharmaceutical Co., Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. (Information on specific API production capacities and product portfolios is often proprietary or available in investor relations materials). [5] Industry reports and market analyses on the pharmaceutical API sector from reputable market research firms (specific reports are not cited individually due to proprietary nature but inform the market trends discussed).

Suppliers and packagers for generic pharmaceutical drug: RANITIDINE HYDROCHLORIDE